F S&P 500
5,330.75 -1.00 (-0.02%) F Dow Jones
39,941.00 -3.00 (-0.01%) F Nasdaq
18,740.75 -22.25 (-0.12%) E-mini Russell 2000 Index Futur
2,105.20 -4.70 (-0.22%) Petróleo
78.84 -0.96 (-1.20%) Oro
2,419.30 -19.20 (-0.79%)
Conduit Pharmaceuticals Inc. (CDT)
Conduit Pharmaceuticals Inc.
4995 Murphy Canyon Road
Suite 300
San Diego, CA 92123
United States
760 471 8536
https://www.conduitpharma.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 7
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. David Joszef Tapolczay | CEO & Director | 419.8k | N/D | 1959 |
| Mr. Adam Sragovicz | Chief Financial Officer | 116.67k | N/D | 1970 |
| Dr. Joanne M. Holland | Chief Scientific Officer | N/D | N/D | 1975 |
Descripción
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
Gestión corporativa
La calificación ISS Governance QuickScore de Conduit Pharmaceuticals Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
